<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">248</article-id><article-id pub-id-type="doi">10.15690/vramn.v67i11.473</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SHORT MESSAGES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">THE ROLE OF INTERLEUKIN-1 AND ASSOCIATED CYTOKINES IN GASTRIC CARCINOGENESIS</article-title><trans-title-group xml:lang="ru"><trans-title>РОЛЬ ЦИТОКИНОВ СЕМЕЙСТВА ИНТЕРЛЕЙКИНА-1 В ЖЕЛУДОЧНОМ КАНЦЕРОГЕНЕЗЕ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Matveeva</surname><given-names>L. V.</given-names></name><name xml:lang="ru"><surname>Матвеева</surname><given-names>Л. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>кандидат медицинских наук, доцент кафедры иммунологии, микробиологии и виру- сологии медицинского института МГУ им. Н.П. Огарева Адрес: 430032, Республика Мордовия, г. Саранск, ул. Ульянова, д. 26а Тел.: (8342) 35-25-16</p></bio><email>MatveevaLjubov1@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mosina</surname><given-names>L. M.</given-names></name><name xml:lang="ru"><surname>Мосина</surname><given-names>Л. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>доктор медицинских наук, профессор кафедры госпитальной терапии медицинского института МГУ им. Н.П. Огарева Адрес: 430032, Республика Мордовия, Саранск, ул. Ульянова, д. 26а Тел.: (8342) 32-19-83</p></bio><email>lardoc@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Medical Institute of N.P. Ogarev Mordovian State University, Saransk, Russian Federation</institution></aff><aff><institution xml:lang="ru">Медицинский институт Мордовского государственного университета им. Н.П. Огарева, Саранск, Российская Федерация</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-11-10" publication-format="electronic"><day>10</day><month>11</month><year>2012</year></pub-date><volume>67</volume><issue>11</issue><issue-title xml:lang="ru">Вестник Российской академии медицинских наук</issue-title><fpage>59</fpage><lpage>65</lpage><history><date date-type="received" iso-8601-date="2015-08-07"><day>07</day><month>08</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, Издательство "Педиатръ"</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/248">https://vestnikramn.spr-journal.ru/jour/article/view/248</self-uri><abstract xml:lang="en"><p><italic>This review presents detailed analysis of scientific data on influence of the associated with interleukin-1 cytokines on the development of malignant tumors of stomach with the definition of spectrum of diagnostic and therapeutic possibilities. Cytokines associated with interleukin-1 directly and indirectly involved into gastric carcinogenesis. Implementation of pro- and contreoncogenic effects depends on many factors. The serological and genetic criteria changes of interleukin-1 have high diagnostic value and prognostic significance opening new differential approaches to the treatment of precancer conditions and gastric cancer.</italic></p><p> </p></abstract><trans-abstract xml:lang="ru"><p><italic>Целью работы был углубленный анализ научных данных о влиянии цитокинов семейства интерлейкина-1 на развитие злокачественных опухолей желудка с определением спектра диагностических и терапевтических возможностей. Цитокины семейства интерлейкина-1 прямо и опосредованно участвуют в желудочном канцерогенезе. Реализация их про- и антионкогенных эффектов определяется многими факторами. Серологические и генетические критерии изменений содержания интерлейкина-1 обладают высокой диагностической ценностью, прогностической значимостью, открывают новые дифференциальные подходы к терапии предопухолевых заболеваний и рака желудка.</italic></p><p> </p></trans-abstract><kwd-group xml:lang="en"><kwd>cytokines</kwd><kwd>interleukin-1</kwd><kwd>cancerogenesis</kwd><kwd>gastric cancer</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>цитокины</kwd><kwd>интерлейкин-1</kwd><kwd>канцерогенез</kwd><kwd>рак желудка</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.	Statistics of malignant tumors in Russia and the CIS in 2009. Vestn. RONTs im. N.N. Blokhina RAMN = Bulletin of N.N. Blokhin RCRC. 2011; 22 (3, app. 1): 172.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.	Sims J.E., Nicklin M.J., Bazan J.F., Barton J.L., Busfield S.J., Ford J.E., Kastelein R.A., Kumar S., Lin H., Mulero J.J., Pan J., Pan Y., Smith D.E., Young P.R. A new nomenclature for IL-1-family genes. Trends Immunol. 2001; 22: 536–537.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.	Tebloeva L.M., Dmitrieva L.A., Grigoryan S.S., Gurevich K.G. New members of the cytokine interleukin-1 and its role in the destructive inflammatory diseases. Med. al'manakh = Med. almanac. 2011; 5 (18): 274–276.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.	Ferrari D., Pizzirani C., Adinolfi E.. Lemoli R.M., Curti A., IdzkoM., Panther E., Di Virgilio F. The P2X7 receptor: a key player in ИЛ-1 processing and release. J. Immunol. 2006; 176: 3877–3883.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.	Giraldo S., Sanchez J., Felty Q., Roy D. IL-1B. Atlas of genetics and cytogenetics in oncology and haematology. 2008. URL:http://AtlasGeneticsOncology.org/Genes/ИЛ1BID40950ch2q13.html</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.	Serebrennikova S.N., Seminskii I.Zh. The role of cytokines in the inflammatory process (message 1). Sib. med. zhurn. = Siberian medical journal. 2008; 6: 5–8.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7.	Ageeva E.S., Shtygasheva O.V., Pulikov A.S., Butorin N.N. The role of IL-1 and IL-8 in pathomorphism gastric mucosa in Helicobacter pylori-associated gastritis. Byull. VSNTs SO RAMN = Bulletin of ESRC SD RAMS. 2011; 1 (77): 16–20.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8.	Arend W.P., Palmer G., Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 2008; 223: 20–38.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.	Dinarello C.A., Fantuzzi G. Interleukin-18 and host defense against infection. J. Infect. Dis. 2003; 187 (2): 370–384.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.	Alboni S., Cervia D., Sugama S., Conti B. Interleukin-18 in the CNS. J. Neuroinflammation. 2010; 7: 9–13.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.	Kozlov V.K. Tsitokinoterapiya: patogeneticheskaya napravlennost' pri infektsionnykh zabolevaniyakh i klinicheskaya effektivnost': Ruk-vo dlya vrachei [Cytokine therapy: pathogenetic focus in infectious diseases and clinical efficacy: Guide for physicians]. St.Petersburg, Al'ter Ego, 2010. 148 p.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12.	Freindlin I.S., Sheikin Yu.A. Endothelial cells as targets and producing cytokines. Med. immunologiya = Med. Immunology. 2001; 3 (4): 499–514.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13.	Starikova E.A., Amchislavskii E.I., Sokolov D.I., Freidlin I.S., Polosukhina E.R. Baryshnikov A.Yu. Changes in the surface phenotype of endothelial cells under the influence of pro-inflammatory and anti-inflammatory cytokines. Med. immunologiya = Med. Immunology. 2003; 5 (1–2): 39–48.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14.	Ketlinskii S.A., Simbirtsev A.S., Vorob'ev A.A. Endogennye immunomodulyatory [Endogenous Immunomodulators]. St.Petersburg, Gippokrat, 1992. 256 p.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15.	Severin E.S., Aleinikova T.L., Osipov E.V., Silaeva S.A. Biologicheskaya khimiya [Biological Chemistry]. Moscow, MIA, 2008. 364 p.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16.	Walecka-Kapica E., Knopik-Dabrowicz A., Klupinska G., Chojnacki J. The assessment of nitric oxide metabolites in gastric juice in Helicobacter pylori infected subjects in compliance with grade of inflammatory lesions in gastric mucosa. Pol. Merkur. Lekarski. 2008; 24 (140): 95–100.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17.	Richikesh M.K., Sadhana S.S. Prostaglandins and cyclooxygenase: their probable role in cancer. Indian J. Farmacol. 2003; 35: 3–12.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18.	Tringali G., Pozzoli G., Vairano M., Mores N., Preziosi P., Navarra P. Interleukin-18 displays effects opposite to those of interleukin-1 in the regulation of neuroendocrine stress axis. J. Neuroimmunol. 2005; 160 (1): 61–67.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19.	Tkach S.M. H. pylori infection as the main cause of gastric carcinogenesis. Zdorov'e Ukrainy = Health of Ukraine. 2009; 1: 32–33.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20.	Fox J.G., Wang T.C. Inflammation, atrophy and gastric cancer. J. Clin. Invest. 2007; 117: 60–69.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21.	McColl K.E., El-Omar E., Gillen D. Helicobacter pylori gastritis and gastric physiology. Gastroenterol. Clin. North Am. 2000; 29: 687–703.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22.	Maev I.V., Kucheryavyi Yu.A., Oganesyan T.S. Allelic polymorphism of interleukin-1β at gelikobakterioza. Ros. zhurn. gastroenterol., gepatol., koloproktol. = Russian journal of gastroenterology, hepatology and colopractology. 2008; 5: 4–11.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23.	Saperas E., Tache Y. Central interleukin-1 beta-induced inhibition of acid secretion in rats: specificity of action. Life Sci. 1993; 52: 785–792.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24.	Hitzler I., Sayi A., Kohler E., Engler D. B., Koch K.N., Hardt W.D., Muller A. Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1β and IL-18. J. Immunol. 2012; 188 (8): 3594–3602.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25.	Bartchewsky W. Jr., Martini M.R., Masiero M., Squassoni A.C., Alvarez M.C., Ladeira M.S., Salvatore D., Trevisan M., Pedrazzoli J.Jr. Effect of Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer. Scand. J. Gastroenterol. 2009; 44 (2): 153–161.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>26.	Day A.S., Su B., Ceponis P.J., Jones N.L., Yau E., Sieveking D., Sherman P.M. Helicobacter pylori infection induces interleukin-18 production in gastric epithelial (AGS) cells. Dig. Dis. Sci. 2004; 49 (11–12): 1830–1835.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>27.	Seino H., Ueda H., Kokai M., Tsuji N.M., Kashiwamura S., Morita Y., Okamura H. IL-18 mediates the formation of stress-induced, histamine-dependent gastric lesions. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 292 (1): 262–267.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>28.	Tu S., Bhagat G., Cui G., Takaishi S., Kurt-Jones E.A., Rickman B., Betz K.S., Penz-Oesterreicher M., Bjorkdahl O., Fox J.G., Wang T.C. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer cell. 2008; 14 (5): 408–419.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>29.	Berezhnaya N.M. The role of immune system cells in the tumor microenvironment. II. The interaction of cells of the immune system with the other components of the microenvironment. Onkolog. = Oncology. 2009; 11 (2): 86–93.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>30.	Kadagidze Z.G. Cytokines. Prakt. onkolog. = Practical oncology. 2003; 4 (3): 131–139.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>31.	Teletaeva G.M. Cytokines and anti-tumor immunity. Prakt. onkolog. = Practical oncology. 2007; 8 (4): 211–218.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>32.	Iigo M., Shimamura M., Matsuda E., Fujita K., Nomoto H., Satoh J., Kojima S., Alexander D.B., Moore M.A., Tsuda H. Orally administered bovine lactoferrin induces caspase-1 and interleukin-18 in the mouse intestinal mucosa a possible explanation for inhibition of carcinogenesis and metastasis. Cytocine. 2004; 25: 36–44.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>33.	Cao R., Farnebo J., Kurimoto M., Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. The FASEB J. 1999; 13 (15): 2195–2202.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>34.	Gracie J.A., Robertson S.E., McInnes I.B. Interleukin-18. J. Leucocyte Biol. 2003; 73: 213–214.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>35.	Sakai K., Kita M., Sawai N., Shiomi S., Sumida Y., Kanemasa K. Levels of interleukin-18 are markedly increased in Helicobacter pylori-infected gastric mucosa among patients with specific IL-18 genotypes. J. Inf. Dis. 2008; 197 (12): 1752–1761.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>36.	Park S., Cheon S., Cho D. The dual effects of interleukin-18 in tumor progression. Cell. Mol. Immunol. 2007; 4 (5): 329–335.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>37.	Macri A., Versaci A., Loddo S., Scuderi G., Travagliante M., Trimarchi G., Teti D., Famulari C. Serum levels of interleukin-1 beta, interleukin-8 and tumor necrosis factor alpha as marcers of gastric cancer. Biomarcers. 2006; 11 (2): 184–193.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>38.	Sun P., Ben Q., Tu S., Dong W., Qi X., Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig. Dis. Sci. 2011; 56 (12): 3596–3601.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>39.	Anisimova N.Yu., Gromova E.G., Kuznetsova L.S., Dolzhikova Yu.I., Boiko N.I., Titov K.S., Antonov A.K., Kiselevskii M.V. Interleukin-17 and interleukin-18 as biomarkers of sepsis in cancer patients. Vestn. sl. krovi Rossii = Bulletin of Russian blood service. 2011; 4: 30–33.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>40.	Hwang I.R., Kodama T., Kikuchi S., Sakai K., Peterson L.E., Graham D.Y., Yamaoka Y. Effect of interleukin 1 polimorphisms on gastric mucosal interleukin-1 beta production in Helicobacter pylori infection. Gasrtoenterology. 2002; 123 (6): 1793–1803.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>41.	El-Omar E.M., Carrington M., Chow W.H., McColl K.E., Bream J.H., Younq H.A., Herrera J., Lissowska J., Yuan C.C., Rothman N., Lanyon G., Martin M., Fraumeni J.F., Rabkin C.S. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000; 404 (6776): 398–402.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>42.	El-Omar E.M., Rabkin C.S., Gammon M.D., Vaughan T.L., Risch H.A., Schoenberg J.B., Stanford J.L., Mayne S.T., Goedert J., Blot W.J., Fraumeni J.F., Chow W.H. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003; 124: 1193–1201.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>43.	Al-Moundhri M.S., Al-Nabhani M., Al-Bahrani B., Burney I.A., Al-Madhani A., Ganquly S.S., Al-Yahyaee S.A., Grant C.S. Intreleukin-1 beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphismus and gastric cancer risk in an Omani Arab population. Gastric Cancer. 2006; 9 (4): 284–290.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>44.	Machado J.C., Pharoah P., Sousa S. Interleukin-1β and interleukin-1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology. 2001; 121 (4): 823–829.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>45.	Zeng Z.R., Hu P.J., Hu S., Pang R.P., Chen M.H., Ng M., Sung J. J. Y. Association of interleukin IL-1β gene polymorphism and gastric cancers in high and low prevalence regions in China. Gut. 2003; 52: 1684–1689.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>46.	Chen A., Li C.N., Hsu P.I., Lai K.H., Tseng H.H., Hsu P.N., Lo G.H., Lo C.C., Lin C.K., Hwang I.R., Yamaoka Y., Chen H.C. Risks of interleukin-1 genetic polymorphisms and Helicobacter pylori infection in the development of gastric cancer. Aliment. Pharmacol. Ther. 2004; 20: 203–211.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>47.	Garza-Gonzalez E., Bosques-Padilla F.J., El-Omar E., Hold G., Tijerina-Menchaca R., Maldonado-Garza H.J., Perez-Perez G.I. Role of polymorphic IL-1B, IL-1RN, and TNF-A genes in distal gastric cancer in Mexico. Int. J. Cancer. 2005; 114: 237–241.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>48.	Lee S.G., Kim B., Choi W., Lee I., Choi J., Song K. Lack of association between pro-inflammatory genotypes of the interleukin-1 (IL-1B31 C/+ and IL-1RN*2/*2) and gastric cancer/duodenal ulcer in Korean population. Cytokine. 2003; 21: 167.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>49.	Matsukura N., Yamada S., Kato S., Tomtitchong P., Tajiri T., Miki M., Matsuhisa T., Yamada N. Genetic differences in interleukin-1β polymorphisms among four Asian populations: an analysis of the Asian paradox between H. pylori infection and gastric cancer incidence. J. Exp. Clin. Cancer Res. 2003; 22: 47–55.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>50.	Furuta T., Shirai N., Sugimoto M. Controversy in polymorphisms of interleukin-1β in gastric cancer risks. J. Gastroenterol. 2004; 39: 501–503.</mixed-citation></ref></ref-list></back></article>
